Table 1.
rpoB Mutations of 83 Mycobacterium tuberculosis Isolates, Their Rifampicin and Rifabutin MIC Distribution Plus Isoniazid Susceptibility Results
| MIC µg/mL | |||||
|---|---|---|---|---|---|
| RIF AD | RIF MGIT | RIF Sensititre | RFB Sensititre | rpoB Mutation | INH |
| 0.25 | 0.25 | 0.25 | ≤0.12 | His526Ser | S |
| 0.5 | 1 | ND | ND | His526-Arg and His526-Tyr | S |
| 2 | 0.5 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 2 | 2 | 0.5 | ≤0.12 | Asp516-Val | R |
| 2 | 2 | ND | ND | Ser531-Leu | S |
| 2 | 0.5 | 0.5 | ≤0.12 | His526Leu | S |
| 2 | 0.25 | 0.25 | ≤0.12 | His526Leu | R |
| 1 | 1 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 2 | 2 | 1 | ≤0.12 | Gln513-Pro | S |
| 2 | 1 | 2 | ≤0.12 | His526Ser | R |
| 2 | 0.25 | 0.5 | ≤0.12 | His526Ser, Asp516Tyr | R |
| 2 | 0.5 | 0.5 | ≤0.12 | Asp516-Tyr | S |
| 1 | 2 | 4 | ≤0.12 | Leu511Pro | S |
| 2 | 2 | 2 | ≤0.12 | Asp516-Tyr | S |
| 2 | 2 | 4 | ≤0.12 | His526Leu | R |
| 0.5 | >2 | 0.25 | ≤0.12 | Leu511Pro | S |
| 1 | 2 | ND | ND | Asp516-Tyr | S |
| 1 | 2 | 2 | ≤0.12 | His526Leu | R |
| 0.5 | 1 | 0.25 | ≤0.12 | Asp516-Tyr | R |
| 1 | 1 | ND | ND | Asp516-Tyr | S |
| 1 | 2 | 2 | ≤0.12 | Leu511Pro | R |
| 1 | 0.5 | 0.5 | ≤0.12 | Asp516-Tyr | R |
| 1 | 2 | 1 | ≤0.12 | Asp516-Tyr and Asp516-Val | R |
| 0.5 | 0.5 | 1 | ≤0.12 | His526Leu | S |
| 0.5 | 0.5 | 0.25 | ≤0.12 | Gln513-Pro | S |
| 0.25 | 0.5 | 0.5 | ≤0.12 | Ser509-Thr and Gln513-Pro | S |
| 0.25 | 0.25 | 0.5 | ≤0.12 | Asp516-Val | R |
| 0.25 | 0.25 | 0.25 | ≤0.12 | Ser509-Thr and Gln513-Pro | S |
| 0.5 | 0.25 | 0.25 | ≤0.12 | Asp516-Tyr | S |
| 0.5 | 0.25 | 0.5 | ≤0.12 | His526-Arg | R |
| 0.25 | 0.25 | ≤0.12 | ≤0.12 | Asp516-Tyr | R |
| 1 | 2 | 1 | ≤0.12 | Asp516-Val | R |
| 2 | 2 | 1 | ≤0.12 | Asp516-Val | R |
| 0.5 | 1 | 8 | 0.5 | His526-Arg and His526-Tyr | S |
| 1 | 0.5 | 0.5 | ≤0.12 | Asp516-Val | S |
| 0.25 | 0.5 | 0.5 | ≤0.12 | Gln513-Pro | R |
| 0.25 | 0.25 | 0.5 | ≤0.12 | Gln513-Pro | S |
| >4 | >2 | 1 | ≤0.12 | Asp516-Val | R |
| 2 | 2 | 2 | 0.25 | Leu511Pro | S |
| 1 | 1 | 1 | 0.25 | Leu511Pro | R |
| 0.25 | 0.25 | ≤0.12 | ≤0.12 | Ser531-Pro | S |
| 1 | 0.5 | 1 | ≤0.12 | Asp516-Tyr | S |
| 1 | 1 | 0.5 | ≤0.12 | Leu511Pro | S |
| 0.5 | 0.5 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 0.5 | 0.5 | 1 | ≤0.12 | Asp516-Tyr | R |
| 0.5 | 0.5 | 1 | ≤0.12 | Asp516-Val | S |
| 0.5 | 0.5 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 0.5 | 0.25 | ≤0.12 | ≤0.12 | Asp516-Val | S |
| 1 | 1 | 0.5 | ≤0.12 | Gln513-Pro and Ser531-Pro | R |
| 0.5 | 0.5 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 1 | 2 | 1 | 0.5 | Asp516-Val and Asp516-Tyr | R |
| 0.5 | 0.5 | 0.5 | ≤0.12 | Ser509-Thr | S |
| 1 | 0.5 | 1 | ≤0.12 | Ser531-Leu | R |
| 0.5 | 1 | 0.5 | ≤0.12 | Leu511Pro | S |
| 2 | 2 | 2 | 0.25 | Asp516-Tyr | R |
| 0.5 | 1 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 1 | ND | 0.5 | ≤0.12 | Asp516-Val | S |
| 0.5 | 0.5 | 0.5 | ≤0.12 | Asp516-Val | S |
| 1 | 0.5 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 0.5 | 1 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 1 | 0.5 | 0.5 | ≤0.12 | Gln513-Pro | R |
| 1 | 0.5 | 0.5 | ≤0.12 | His526-Arg and His526-Tyr | S |
| 1 | 1 | 0.5 | ≤0.12 | Asp516-Val | R |
| 1 | 1 | 0.5 | ≤0.12 | Asp516-Tyr and Asp516-Val | S |
| 0.5 | 1 | ≤0.12 | ≤0.12 | Asp516-Tyr and Asp516-Val | S |
| 0.5 | 0.5 | ≤0.12 | ≤0.12 | Gln513-Pro | S |
| 1 | 2 | 1 | 1 | Asp516-Val | R |
| 2 | 0.25 | 0.5 | ≤0.12 | Gln513-Pro | R |
| 0.25 | 0.25 | 0.25 | ≤0.12 | Gln513-Pro | R |
| 2 | 0.25 | 1 | ≤0.12 | Gln513-Pro | R |
| 0.5 | 1 | 0.25 | ≤0.12 | Gln513-Pro | R |
| 0.5 | 1 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 2 | 2 | 2 | ≤0.12 | Asp516-Val | S |
| ≤0.125 | ≤0.125 | ≤0.12 | ≤0.12 | Asp516-Val | S |
| 1 | 1 | 0.5 | ≤0.12 | His526-Arg and His526-Tyr | S |
| 0.25 | ≤0.125 | ≤0.12 | ≤0.12 | Ser531-Leu | S |
| 0.25 | 0.25 | ≤0.12 | ≤0.12 | Asp516-Tyr and Asp516-Val | S |
| 0.5 | 0.5 | 2 | 0.25 | Gln513-Pro | S |
| 1 | 2 | 0.5 | 0.12 | Asp516-Val | R |
| 0.5 | 0.25 | 0.5 | ≤0.12 | Gln513-Pro | S |
| 1 | 1 | 0.5 | ≤0.12 | Asp516-Val | R |
| 0.5 | 0.5 | 0.5 | 0.25 | His526-Leu | S |
| ≤0.125 | ≤0.125 | 1 | 1 | ND | S |
Abbreviations: AD, agar dilution; INH, isoniazid; MGIT, Mycobacteria Growth Indicator Tube; MIC, minimum inhibitory concentration; ND, not done; R, resistant; RFB, rifabutin; RIF, rifampicin; S, susceptible.